Human Recombinant PAI-1 (from E. coli)

Supplier: PEPROTECH INC.
Ratings: (No Reviews)

Total Ratings: 0
Avg. Ratings: 0.0 out of 5

140-04-2UG 140-04-10UG 140-04-50UG 140-04-100UG 140-04-250UG 140-04-500UG 140-04-1MG
10779-376EA 139.89 USD
10779-376 10779-378 10779-380 10779-382 10779-384 10779-386 10779-388
Human Recombinant PAI-1 (from E. coli)
Proteins and Peptides

Plasminogen Activator Inhibitor-1 (PAI-1, Serpin E1) is a member of the serpin family of serine protease inhibitors, and is the primary inhibitor of urokinase and tissue plasminogen activator (tPA). PAI-1 is expressed predominantly in adipose, liver and vascular tissues, but is also produced by certain tumor cells. Elevated levels of PAI-1 are associated with obesity, diabetes and cardiovascular disease, and increased production of PAI-1 is induced by various obesity-related factors, such as TNFα, glucose, insulin, and very-low-density lipoprotein. The obesity-related elevation of PAI-1 levels, along with the consequential deficiency in plasminogen activators, can lead directly to increased risk of thrombosis and other coronary diseases. Accordingly, PAI-1 has been implicated as an important molecular link between obesity and coronary disease. PAI-1 can also specifically bind vitronectin (VTN) to form a stable active complex with an increased circulatory half-life relative to free PAI-1. Recombinant Human PAI-1 is a 42.7 kDa protein containing 379 amino acid residues.


Ordering information: For research use only. Not for use in diagnostic or therapeutic procedures.

Order Now


Learn more

About VWR

Avantor is a vertically integrated, global supplier of discovery-to-delivery solutions for...

Learn more About VWR